Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• European American patients with DNA available and designated case or control

• African American patients with DNA available and designated case or control status

• Patients who developed grade 2-4 for African American (AA) and grade 3-4 for European American (EA) peripheral neuropathy during their treatment with paclitaxel and who did not develop peripheral neuropathy following a full course of treatment with paclitaxel

Locations
United States
Massachusetts
Eastern Cooperative Oncology Group
RECRUITING
Boston
Time Frame
Start Date: 2014-03-25
Estimated Completion Date: 2100-01-01
Participants
Target number of participants: 575
Treatments
Ancillary-Correlative (whole exome sequencing)
Previously collected germline DNA samples are analyzed via whole exome sequencing.
Related Therapeutic Areas
Sponsors
Leads: National Cancer Institute (NCI)

This content was sourced from clinicaltrials.gov